

# Christina L Addison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4067690/publications.pdf>

Version: 2024-02-01

56  
papers

1,636  
citations

411340  
20  
h-index

340414  
39  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3279  
citing authors

#	ARTICLE	IF	CITATIONS
1	VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models. <i>British Journal of Cancer</i> , 2022, , .	2.9	0
2	Focal Adhesion Kinase Inhibitors Prevent Osteoblast Mineralization in Part Due to Suppression of Akt-mediated stabilization of Osterix. <i>Journal of Bone Oncology</i> , 2022, , 100432.	1.0	2
3	Mapping vitamin B <sub>6</sub> metabolism by hydrazoCEST magnetic resonance imaging. <i>Chemical Communications</i> , 2021, 57, 10867-10870.	2.2	5
4	Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2911.	1.8	4
5	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5788.	1.8	11
6	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019, 16, 43.	1.1	16
7	Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. <i>Molecular Oncology</i> , 2018, 12, 423-440.	2.1	54
8	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 41.	1.1	33
9	The plasma peptidome. <i>Clinical Proteomics</i> , 2018, 15, 39.	1.1	22
10	Co-inhibition of mTORC1, HDAC and ESR1± retards the growth of triple-negative breast cancer and suppresses cancer stem cells. <i>Cell Death and Disease</i> , 2018, 9, 815.	2.7	34
11	A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. <i>Lung Cancer</i> , 2017, 104, 65-69.	0.9	19
12	MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2. <i>PLoS ONE</i> , 2017, 12, e0185619.	1.1	17
13	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0150567.	1.1	32
14	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 771-785.	0.8	66
15	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	1.0	9
16	Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions. <i>Journal of Bone Oncology</i> , 2016, 5, 180-184.	1.0	1
17	Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast. <i>Breast Journal</i> , 2016, 22, 45-53.	0.4	14
18	Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER± coinhibition. <i>FEBS Letters</i> , 2016, 590, 4606-4616.	1.3	28

#	ARTICLE	IF	CITATIONS
19	Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. <i>Journal of Bone Oncology</i> , 2015, 4, 47-53.	1.0	7
20	Treatment choices for patients with invasive lobular breast cancer: a doctor survey. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 740-748.	0.9	12
21	Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer. <i>International Journal of Surgical Oncology</i> , 2015, 2015, 1-9.	0.3	10
22	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015, 28, 210-224.	7.7	77
23	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015, 21, 530-536.	15.2	118
24	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.4	375
25	Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations. <i>Clinical Breast Cancer</i> , 2015, 15, 421-425.	1.1	33
26	Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. <i>Clinical Lung Cancer</i> , 2015, 16, e189-e201.	1.1	6
27	Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. <i>Lung Cancer</i> , 2015, 90, 288-295.	0.9	6
28	Pharmacotherapy of bone metastases in breast cancer patients – an update. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1109-1118.	0.9	8
29	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014, 3, 577.	1.2	18
30	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 615-624.	1.1	25
31	Bone-targeted therapy for metastatic breast cancer – Where do we go from here? A commentary from the BONUS 8 meeting. <i>Journal of Bone Oncology</i> , 2014, 3, 1-4.	1.0	5
32	Essential role for the SLK protein kinase in embryogenesis and placental tissue development. <i>Developmental Dynamics</i> , 2014, 243, 640-651.	0.8	13
33	De-escalated administration of bone-targeted agents in patients with breast and prostate cancer – A survey of Canadian oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 77-83.	1.0	24
34	Does estrogen play a role in response to adjuvant bone-targeted therapies?. <i>Journal of Bone Oncology</i> , 2013, 2, 167-173.	1.0	6
35	A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. <i>Journal of Bone Oncology</i> , 2013, 2, 123-131.	1.0	21
36	Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. <i>Journal of Bone Oncology</i> , 2013, 2, 105-109.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Incidence and consequences of bone metastases in lung cancer patients. <i>Journal of Bone Oncology</i> , 2013, 2, 22-29.	1.0	78
38	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. <i>Journal of Bone Oncology</i> , 2013, 2, 154-157.	1.0	15
39	Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 38-46.	1.0	14
40	miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels. <i>PLoS ONE</i> , 2013, 8, e70515.	1.1	42
41	Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. <i>Journal of Clinical Medicine</i> , 2013, 2, 67-88.	1.0	7
42	Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: Are we changing outcomes?. <i>Journal of Clinical Oncology</i> , 2013, 31, e16074-e16074.	0.8	1
43	Breast cancer biomarker discordance between primary and sites of metastasis: A systematic review.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11574-e11574.	0.8	0
44	Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8048-8048.	0.8	1
45	Î²1 integrin. <i>Cell Adhesion and Migration</i> , 2012, 6, 71-77.	1.1	53
46	Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?. <i>Journal of Bone Oncology</i> , 2012, 1, 12-17.	1.0	12
47	Î²1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner. <i>Cancer Letters</i> , 2012, 316, 157-167.	3.2	16
48	RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA. <i>Vascular Cell</i> , 2012, 4, 1.	0.2	40
49	Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 453-457.	1.1	10
50	Serum activinA and TGF-Î² as biomarkers of breast cancer bone metastasis behavior.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10620-10620.	0.8	0
51	Focal adhesion kinase inhibitors are potent anti-angiogenic agents. <i>Molecular Oncology</i> , 2011, 5, 517-526.	2.1	74
52	Plasma Transforming Growth Factor Î± and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21. <i>Journal of Clinical Oncology</i> , 2010, 28, 5247-5256.	0.8	51
53	Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. <i>Cancer Letters</i> , 2007, 252, 195-207.	3.2	16
54	The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. <i>Experimental Cell Research</i> , 2006, 312, 2476-2489.	1.2	20

#	ARTICLE	IF	CITATIONS
55	Modulation of response to tumor therapies by the extracellular matrix. <i>Future Oncology</i> , 2006, 2, 417-429.	1.1	10
56	The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent. <i>BMC Cell Biology</i> , 2005, 6, 38.	3.0	27